Agustin Garcia

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

Franco M. Muggia, John D. Hainsworth, Susan Jeffers et al. · Journal of Clinical Oncology · 1997 · 657 citations

Medicine, Oncology, Pharmacology +17

ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases

Priya Kumthekar, Shou‐Ching Tang, Andrew Brenner et al. · Clinical Cancer Research · 2020 · 243 citations

Medicine, Oncology, Pharmacology +17

Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

Ignace Vergote, John P. Micha, Charles H. Pippitt et al. · Journal of Clinical Oncology · 2010 · 26 citations

Medicine, Oncology, Pharmacotherapy +16

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer

Gordon Rustin, Ignace Vergote, John P. Micha et al. · Gynecologic Oncology · 2017 · 10 citations · Full text

Medicine, Oncology, Pharmacology +17